PDS Biotechnology Corporation’s filing revealed that its Director Freitag Gregory Gene acquired Company’s shares for reported $25000.0 on Feb 28 ’25. In the deal valued at $1.66 per share,15,060 shares were bought. As a result of this transaction, Freitag Gregory Gene now holds 61,213 shares worth roughly $69170.68999999999.
Then, Glover Stephen C. bought 15,061 shares, generating $25,001 in total proceeds. Upon buying the shares at $1.66, the Director now owns 78,851 shares.
B. Riley Securities initiated its PDS Biotechnology Corporation [PDSB] rating to a Buy in a research note published on November 01, 2022; the price target was $10. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late June with a ‘”an Overweight”‘ rating. H.C. Wainwright also remained covering PDSB and has increased its forecast on November 10, 2020 with a “Buy” recommendation from previously “Neutral” rating. Alliance Global Partners started covering the stock on May 27, 2020. It rated PDSB as “a Buy”.
Price Performance Review of PDSB
On Tuesday, PDS Biotechnology Corporation [NASDAQ:PDSB] saw its stock jump 0.89% to $1.13. Over the last five days, the stock has lost -0.88%. PDS Biotechnology Corporation shares have fallen nearly -65.02% since the year began. Nevertheless, the stocks have fallen -30.67% over the past one year.
How much short interest is there in PDS Biotechnology Corporation?
A steep rise in short interest was recorded in PDS Biotechnology Corporation stocks on 2025-07-15, growing by 0.46 million shares to a total of 2.44 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 1.99 million shares. There was a rise of 18.69%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 09, 2020 when Noble Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $5.45 price target.
